Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001

NCT03115073 is registered in ClinicalTrials.gov with ProFem GmbH as lead sponsor.

NCT NCT03115073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03115073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001
Lead sponsor
ProFem GmbH
Phase
Phase 2/3
Overall status
Completed
Start date
April 4, 2017
Completion date
July 30, 2018
Enrollment
84 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

vulvovaginal candidiasis (vvc)